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Abstract 
Glioblastoma multiforme (GBM) is the most common and malignant brain tumor 
in adults, affecting thousands of people worldwide every year, with a life expectancy, 
post diagnosis of 12 months. Surgery, radiotherapy and chemotherapy together, result in 
an overall mean survival not exceeding 15 months. Targeted therapeutic agents sorafenib, 
an oral multi kinase inhibitor, and lapatinib, an epidermal growth factor receptor (EGFR) 
inhibitor, used in combination have been shown to kill GBM cells be through inhibition 
of major growth mediating signaling pathways that are frequently over expressed in 
gliomas, including mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-
kinase/ protein kinase B (PI3K/AKT). Sorafenib can restore lapatinib induced 
cytotoxicity by down regulation of myeloid cell leukaemia-1 (Mcl-1) expression. Prior 
studies have shown Mcl-1 to play an important role in resistance to lapatinib. 
Furthermore, data indicated that this drug combination is able to trigger activation of 
autophagic and apoptotic pathways and induce endoplasmic reticulum (ER) stress 
response in GBM cells, collectively resulting in cell death. In conclusion, data presented 
here demonstrates that the combination of sorafenib and lapatinib can kill GBM cells in a 
greater than additive fashion, through induction of autophagy, apoptotic events (extrinsic 
and intrinsic) and ER stress.
11 
 
Introduction 
 
Glioblastoma Multiforme 
 
 Glioblastoma multiforme (GBM) is the most common and lethal primary 
malignant brain tumor in adults.
18,54,64
 Its prognosis remains dismal since the majority of 
glioblastomas develop very rapidly without any clinical evidence with the median 
survival time not exceeding 15 months, even with the available therapies.
18,54,63,64
 In the 
United States, about 20,000 people are diagnosed with GBM annually and the number of 
patients diagnosed with this aggressive malignancy is increasing globally.
63
 The main 
reasons for the lethality of glioblastomas include the highly invasive nature of tumor 
cells, the resistance of these cells to chemotherapeutics in the brain micro-environment 
and the existence of blood-brain barrier, which makes it difficult for therapeutic agents to 
reach and remain in the brain tissue adequately.
57
 Therefore, there is an urgent need for 
new therapies which can fight this fatal disease more effectively. The advent of molecular 
targeted therapies was a turning point in the battle against cancer, and these novel 
molecular inhibitors have been subject to many in vitro and in vivo studies ever since. 
Currently, there are several targeted agents in clinical trial for the treatment of patients 
with GBM as individual agents or in combination with radiation and chemotherapy and 
their efficacy is yet to be determined.
18
 These therapeutic agents are selected based upon 
their capacity to modulate the signal transduction pathways that are commonly 
dysregulated in GBM cells such as mitogen-activated protein kinase (MAPK) and 
phosphatidylinositol 3-kinase (PI3K) which result in abnormal cellular growth and 
proliferation.
58,64
 Table 1 provides the names and characteristics of four GBM cell lines 
used in this study. 
12 
 
Cell Line Characteristics 
GBM5 Over expresses PDGFRα, Mutant PI3K 
GBM6 Mutant Variant - EGFR vIII 
GBM12 Expresses mutant active full length EGFR 
GBM14 Mutant PTEN 
Table 1. The list of GBM cells used in the study and their mutational characteristics. 
 
Conventional Therapy  
 
 The conventional therapy for patients with GBM include surgical removal of 
tumor to the extent feasible, followed by adjuvant high-dose radiotherapy and 
chemotherapy.
18,54
 Currently, the common chemotherapeutic used in this treatment is 
temozolomide (TMZ), an oral alkylating agent. TMZ induces the formation of O
6
-
methylguanine in DNA, which mispairs with thymine during the next cycle of DNA 
replication resulting in double strand breaks and eventually activation of apoptotic 
pathways.
5,20
 The previous studies have shown that the median survival time of patients 
receiving radiotherapy and TMZ concomitantly was 14.6 months as compared to 12.1 
months with radiotherapy alone.
54
 Unfortunately, this clinically meaningful survival 
benefit is overshadowed by the harsh toxicity and devastating side effects in GBM 
patients. The limited success of TMZ is mainly due to chemoresistance and the inability 
of TMZ to induce apoptosis.
5
 The ability of alkylating agents to induce apoptosis depends 
upon O
6
-methylguanine-DNA methyltransferase (MGMT) activity and the activity of 
various survival pathways.
5
 MGMT is an important DNA repair enzyme, and methylation 
of its promoter has been shown to extend the median survival time of GBM patients who 
received concurrent radiotherapy and TMZ by 6.4 months.
20
 Tumor tissue samples from 
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patients receiving TMZ treatment indicated that AKT and Extracellular Signal-Regulated 
Kinase (ERK)1/2 were phosporylated.
5
 In a similar study, Hirose et al 
21
 showed that 
activation of AKT protects GBM cells from TMZ-induced cytotoxicity. Moreover, it was 
reported that the chemo resistance of GBM cells to TMZ was partially diminished with 
inhibitors of PI3K/AKT and ERK1/2/ MAP kinase pathways.
5
 Collectively, the findings 
presented here elucidate the significance of these cellular survival pathways in GBM cells 
and suggest that they can potentially serve as targets for future therapeutic treatment. 
                                                                               
Targeted Therapy 
 Typically, conventional chemotherapy does not discriminate between rapidly 
dividing normal cells and cancer cells, has low therapeutic efficacy and often produces 
palliative and unpredictable responses. In contrast, targeted therapies only interfere with 
molecular targets within tumor cells, have a high specificity and cause less toxicity.
3
 
Therefore, targeted therapy represents a more promising approach based upon the 
molecular understanding of tumorigenesis, which may potentially replace conventional 
cytotoxic chemotherapy in the near future. A major setback to this novel therapy is the 
potential for crosstalk between cellular survival pathways. This may result in the cell 
activating an alternative survival pathway in the event of blockade of a specific pathway; 
thus, leading to drug resistance.  For instance, recent clinical trials revealed that EGFR 
tyrosine kinase inhibitors, used as single agents, are of little therapeutic benefit in patients 
with GBM, which commonly possess deregulated EGFR signaling pathway.
58
 Therefore, 
there is growing evidence that the use of targeted therapeutics in combination provides a 
more rational strategy to increase the efficacy of treatment.  
14 
 
 There are multiple types of targeted therapeutics available, including monoclonal 
antibodies, antisense inhibitors of growth factor receptors, and most importantly, 
inhibitors of tyrosine kinases.
3
 The two targeted therapeutics used in this study, sorafenib, 
a multi serine/threonine/tyrosine kinase inhibitor, and lapatinib, an inhibitor of EGFR 
tyrosine kinase, will be introduced in the following section. 
 
Sorafenib 
 Sorafenib (BAY 43-9006, Nexavar) is an oral multi kinase inhibitor, which was 
primarily designed to inhibit Raf kinase, a serine/threonine kinase, but was shown to have 
an inhibitory effect on mutant Raf and a variety of tyrosine kinases including vascular 
endothelial growth factor receptor (VEGFR) 2/3, platelet-derived growth factor receptor-
β (PDGFRβ), FLT3, Ret, and c-Kit with half maximal inhibitory concentrations (IC50) in 
the nanomolar ranges.
24,30,40,41,53,61
 The development cycle of sorafenib took 
approximately 11 years and it was approved by Food and Drug Administration (FDA) in 
December 2005 for the treatment of advanced renal cell carcinoma (RCC).
60 
                               
Figure 1. Chemical structure of sorafenib tosylate.
24 
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Crystallographic analyses of sorafenib interaction with the kinase domain of B-
Raf revealed that the inhibitor bound to the ATP-binding pocket, thus inhibiting substrate 
binding and phosphorylation.
42 
In vivo and in vitro studies have indicated the ability of sorafenib to inhibit tumor 
growth and tumor microvasculature through anti-proliferative, anti-angiogenic, and pro-
apoptotic effects.
61
 Recent studies concerned with the mechanism of action of sorafenib 
have shown the induction of cell death through a process involving induction of ER stress 
leading to down-regulation of anti-apoptotic protein, Mcl-1.
40,41 
 Sorafenib toxicity has been well tolerated by patients who received up to 800 
milligrams (mg) of the drug per day and the side effects have been limited to fatigue, 
diarrhea and hand or foot skin reactions.
50,52 
 
Lapatinib 
 Lapatinib (GW-572016, Tykerb) is a tyrosine kinase inhibitor which inhibits 
EGFR/ErbB-1 and Her-2/ErbB-2 signaling, with IC50 values of 10.2 and 9.8 nanomolar 
respectively.
6,32,58,62
 In January 2010, lapatinib was granted accelerated FDA approval to 
be used in combination with letrozole for the treatment of hormone receptor positive 
metastatic breast cancer that over-express ErbB-2 receptor.
32,56
 Lapatinib exhibits 
reversible, non-covalent inhibition of EGFR and ErbB-2 by binding in the ATP-binding 
cleft located on the intracellular kinase domain of these receptors; thus leading to 
inactivation of downstream signal proteins.
32,62
 Computational studies have shown that 
binding of lapatinib to the ATP binding pocket of EGFR receptors perturbs their three 
dimensional structure and results in accumulation of inactive EGFR dimmers on the cell 
16 
 
surface. These inactive dimers serve as ligand traps, since they are able to bind the 
growth factor molecules without receptor phosphorylation at the kinase domain.
46 
Although EGFR is amplified or mutated in nearly half of GBM cells, molecular 
inhibitors of this receptor have not yielded high efficacy in clinical trials, indicating the 
existence of resistance mechanisms.
7
 Consequently, a phase I/II clinical study of lapatinib 
in recurrent GBM failed to produce any appreciable benefit.
58
 Resistance to EGFR 
inhibitors occurs mainly through secondary mutations in the receptors, through activation 
of alternative tyrosine kinase pathways, or through over-expression of anti-apoptotic 
proteins, specifically Mcl-1.
8,34
 Recent studies have demonstrated that lapatinib resistance 
is mediated by elevated expression of Mcl-1 and not by secondary mutation of EGFR 
receptors.
32-34
   
 Lapatinib caused minimal toxic effects in patients who received up to 1500 mg of 
the drug per day with the adverse events being limited to diarrhea, rash, nausea, and 
fatigue.
6 
 
 
Figure 2. Chemical structure of lapatinib.
26  
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Epidermal Growth Factor Receptor Tyrosine Kinase 
 The EGFR/ErbB family is a critical component in the autocrine growth regulation 
of carcinoma, and is comprised of four different receptors; EGFR/ErbB1, ErbB2/HER2, 
ErbB3/HER3, and ErbB4/HER4.
47
 All of these trans-membrane proteins are within the 
170-190 kilo Dalton (kDa) size range and are composed of three different domains; the 
extracellular ligand-binding domain, hydrophobic trans-membrane domain, and 
intracellular catalytic domain.
27,47
 The hydrophobic domain anchors the receptor in the 
membrane and connects the cysteine-rich growth factor binding extracellular domain to 
the intracellular tyrosine kinase catalytic domain.
47
 Unlike ErbB1, 2 and 4 which are 
catalytically active, ErbB3 does not have an active tyrosine kinase domain, but remains 
competent for ligand binding and signal transduction.
62
 Ligand binding or receptor over-
expression induces homo- or hetero-dimerization of ErbB receptors, which results in 
trans-phosphorylation of tyrosine residues located on the intracellular catalytic domain.
47
 
The phospho-tyrosine residues on the cytoplasmic side of the receptor act as docking 
sites for Src homology 2 (SH2) domain-containing signaling proteins that are involved in 
activation of multiple downstream metabolic signaling cascades including PI3K/AKT 
and Ras/Raf/MAPK.
17,38,47 
 EGFR is amplified in approximately 40-50% and over-expressed in more than 
60% of glioblastomas. Nearly 40% of the GBMs with EGFR amplification possess a 
constitutively active mutant form of the receptor, EGFRvIII.
36,38
 This mutation leads to 
deletion of exons 2-7 of the EGFR gene, which makes the receptor incapable of binding 
to any known ligand.
16
 It has been shown that EGFRvIII plays a significant role in 
chemo-resistance, most notably by activating PI3K/AKT signaling pathway and its 
18 
 
downstream targets such as mammalian target of rapamycin (mTOR).
16
 As a result, new 
approaches to the treatment of recurrent GBM mostly include combinations of targeted 
therapeutics that can inhibit both EGFRs and their downstream signaling cascades 
simultaneously.
36
  
 
Mitogen-Activated Protein Kinase Pathway (MAPK) 
 MAPK pathways are evolutionary conserved signaling cascades that transduce 
extracellular signals to the fundamental intracellular processes such as growth, 
proliferation, migration and apoptosis.
11
 MAPK pathways consist of a three-tier kinase 
module in which a downstream MAPK is activated upon phosphorylation by MAPK 
kinase (MAPKK), which in turn is activated when phosphorylated by its upstream 
MAPK kinase kinase (MAPKKK).
11,42
 There are four major, well characterized 
mammalian MAPK kinase pathways that activate four distinct terminal serine/threonine 
kinases, ERK1/2, c-Jun amino-terminal kinase (JNK), p38 kinase and ERK5 (Figure 3).
42
 
While ERK1/2 is normally activated by growth factors, JNK, p38 and ERK 5 usually 
become activated in response to environmental stress such as osmotic shock and ionizing 
radiation.
11,42
 Recently, two more mammalian MAPK pathways have been discovered 
that lead to activation of ERK3/4 and ERK 7/8 while the rest of the components of these 
pathways are currently unknown.
11
 Among all, the ERK1/2 MAPK signaling pathway, 
commonly deregulated in GBM, has drawn a great deal of attention due to its pivotal role 
in vital cell functions including growth, differentiation, survival migration and 
angiogenesis, and has grown as a major target for cancer drug discovery.
11,39 
19 
 
 
 
Figure 3. Four major mammalian MAPK pathways.
42
 MAPK pathways are comprised 
of three-tier kinase module in which a MAPKKK phosphorylates the downstream 
MAPKK, which in turn phosphorylates its downstream serine/threonine MAPK. Among 
the MAPKs activated by these four pathways, only ERK1/2 responds to growth factors. 
ERK5, JNK and p38 are mainly activated due to environmental stress such as osmotic 
shock and ionizing radiation. 
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Ras/Raf/MAPK Pathway 
 When growth factors bind to their receptors, they induce dimerization and auto-
phosphorylation of tyrosine residues on the catalytic domains of these receptors. These 
phospho-tyrosines act as docking sites for growth factor receptor-bound protein 2 
(GRB2), an adaptor protein, and sons of sevenless (SOS), an exchange factor, which 
together result in the activation of Ras (Figure 4).
25
  
Ras GTPases act as molecular switches that mediate activation of many signaling 
pathways.
11
 Inactive guanosine diphosphate (GDP)-bound Ras activity is regulated by 
guanine nucleotide exchange factors (GEFs), such as SOS, which promote the formation 
of active guanosine triphosphate (GTP)-bound Ras, whereas GTPase-activating proteins 
(GAPs), such as neurofibromin 1 (NF1), induce GTP hydrolysis and formation of 
inactive GDP-bound Ras.
11,42
 Activated GTP-bound Ras then recruits Raf from the 
cytosol to the cell membrane where a multi step activation process occurs.
25
 Although 
Ras is commonly mutated in a variety of cancers, mutations in Ras have rarely been 
reported in GBM.
39
  
 Raf serine/threonine kinases are direct effectors of Ras and work at the apex of 
this pathway. There are different mutant forms of Raf whose structures are similar, but 
differ considerably in their modes of regulation, tissue distribution, and the ability to 
activate MAPK/ERK kinase (MEK).
11
 Raf-1 is expressed in all tissues, whereas A-Raf is 
predominantly found in urogenital tissue and B-Raf in neural tissue and testis.
25
 All three 
isoforms are able to phosphorylate MEK with B-Raf being the strongest activator and A-
Raf the weakest.
25
 Both wild type B-Raf and constitutively active mutant B-Raf V600E, 
21 
 
that is overexpressed in 15-20% of high-grade pediatric gliomas, are inhibited by 
sorafenib.
10,42,60
  
Activated Raf then phosphorylates MEK1/2 at two serine residues located on the 
kinase domain, which in turn binds to and phosphorylates ERK1/2. Activated ERK1/2 
can translocate to the nucleus and induce genetic responses that regulate processes such 
as proliferation, differentiation, survival, migration and angiogenesis.
11,25 
 
PI3K/AKT Pathway 
 When growth factors bind to the membrane receptor tyrosine kinases including 
EGFR, PDGFR and Insulin-like growth factor 1 receptor (IGFR), they induce receptor 
phosphorylation and membrane recruitment of PI3K.
9,45
 PI3K is a lipid kinase that is 
comprised of two separate subunits, a regulatory p85 and a catalytic p110, which 
heterodimerize upon activation.
9,29
 Activated PI3K phosphorylates the lipid 
phosphatidylinositol 4,5-biphosphate (PIP2) generating the second messenger 
phosphatidylinositol 3,4,5-triphosphate (PIP3).
9,29,45
 PIP3 in turn recruits both 
phosphatidylinositol-dependent kinase 1 (PDK1) and AKT to the membrane, where AKT 
becomes phosphorylated by PDK1 and mTORC2/rapamycin-insensitive companion of 
mTOR(Rictor) to become fully active (Figure 5).
9,45
 Activated serine/threonine AKT 
induces several different cellular responses, such as protein synthesis, survival, migration 
and apoptosis through phosphorylation of multiple downstream effectors.
4
 Among all of 
the AKT targets, mTOR has a critical role as a nutrient sensor and is generally 
deregulated in a variety of cancers including GBM.
9,45
 Activated mTOR phosphorylates  
22 
 
 
 
 
Figure 4. Ras/Raf/MAPK signaling pathway. Upon ligand binding, the tyrosine 
residues on the kinase domain of EGFRs become transphosphorylated, which act as 
docking sites for the adaptor protein GRB2. SOS binds to GRB2 and activates Ras by 
exchanging GDP for GTP. GTP-bound Ras recruits Raf from cytosol to the membrane 
and activates it, which in turn activates MEK1/2 by phosphorylating two distinct serine 
residues. Activated MEK1/2 then phosphorylates ERK1/2 that translocates in the nucleus 
and induces multiple cellular responses.  
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p70S6 kinase (p70S6K) and eukaryotic initiation factor 4E (eIF4E)-inhibitory binding 
protein (4EBP) resulting in activation of p70S6K and eIF4E and increase in protein 
synthesis consequently.
9,45 
 The PI3K/AKT pathway is negatively regulated by phosphatase and tensin 
homolog (PTEN), a lipid phosphatase that dephosphorylates PIP3 to PIP2.
4,9,45
 Mutations 
of PTEN occurs in 15-40% of GBM, and results in constitutive activation of AKT 
pathway and cannot be compensated for by any other tumor suppressor.
45 
 
Apoptosis: Intrinsic and Extrinsic Pathways 
 Apoptosis, also referred to as programmed cell death type I (PCDI), is an energy-
dependent multi-step biochemical process that plays a crucial role in tissue homeostasis 
in multicellular organisms, and its deregulation contributes to many diseases, including 
cancer, autoimmunity and AIDS.  Morphologically, apoptosis is characterized by 
membrane blebbing, cell shrinkage, nucleus fragmentation, chromatin condensation and 
DNA degradation.
13,48,51
 There are two distinct apoptotic pathways: the extrinsic or death 
receptor pathway and the intrinsic or mitochondrial pathway. However, new evidence 
suggested that these two pathways are connected and the components of one pathway can 
influence the other.
13
 Both extrinsic and intrinsic pathways converge on the activation of 
specific intracellular poteases, the caspase family. Caspases are intracellular cysteine 
proteases that cleave proteins next to aspartate residues. Caspases, typically categorized 
into initiators and executioners, are synthesized as inactive zymogens and become 
activated upon cleavage by their upstream modulators.
13,65
 Caspase 3 is the most  
24 
 
 
 
Figure 5. PI3K/AKT signaling pathway. The lipid kinase PI3K binds the kinase 
domain of the EGFR receptor, and phosphorylates PIP2 to generate PIP3, a second 
messenger. PIP3 recruits both PDK1 and AKT to the membrane where PDK1 
phosphorylates AKT. Activated AKT induces protein synthesis and survival through 
interaction with various substrates. mTOR, a major AKT target that acts as a nutrient 
sensor,  phosphorylates p70S6K and 4EBP. Released eIF4E and phospho-p70S6K 
translocate to the nucleus and induce protein synthesis. This pathway is negatively 
regulated by phosphatase PTEN, which dephosphorylates PIP3 to PIP2. 
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important of the executioner caspases, and is activated by any of the initiator caspase 8, 9 
and 10 in both extrinsic and intrinsic pathways. Executioner caspases (caspase 3, 6 and 7) 
cleave various substrates including cytoskeletal and nuclear proteins, and also activate 
other proteases and endonucleases involved in protein degradation and DNA 
fragmentation.
13,65 
Unlike the extrinsic pathway that is mediated by death receptors, the intrinsic 
pathway is strictly controlled by the B-cell lymphoma-2 (Bcl-2) family of proteins.
13,65
 
The Bcl-2 family consists of three different classes: the anti-apoptotic group I, the pro-
apoptotic group II and group III proteins that bind and regulate the activity of anti-
apoptotic group II proteins. Group I family members such as Bcl-2, Bcl-x long (Bcl-xL) 
and myeloid cell leukaemia-1 (Mcl-1) directly bind and inhibit pro-apoptotic group II 
family members including Bcl-2-associated X protein (Bax) and Bcl-2 homologous 
antagonist/killer (Bak). Whereas, the group III family members including p53 
unregulated modulator of apoptosis (Puma), NADPH oxidase activator (Noxa), BH3 
interacting domain death agonist (BID) and Bcl-2 interacting mediator of cell death 
(BIM) interact with pro-apoptotic group II family members and induce their insertion in 
the mitochondrial membrane.
13,48,65
 Recent studies have demonstrated a role for the tumor 
suppressor p53 in synthesis of Puma and Noxa, linking DNA damage to apoptotic cell 
death.
37,66 
The intrinsic pathway is activated by various stimuli such as viral infection, DNA 
damage and absence of certain growth factors, hormones and cytokines. After exposure 
to these stimuli, Bax and Bak are inserted in the outer membrane of mitochondria leading 
to mitochondrial membrane permeabilization, formation of pores, and release of 
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cytochrome-c and other pro-apoptotic proteins, such as caspase-activated 
deoxyribonuclease (CAD), apoptosis-inducing factor (AIF) and endonuclease G, from the 
inter-membrane space into the cytosol.
13,65
 In the cytosol, cytochrome-c binds apoptotic 
protease-activating factor-1 (Apaf-1), which in turn binds pro-caspase 9 to form a 
complex known as the apoptosome. Binding to Apaf-1 induces conformational change 
and activation of caspase 9, which proteolytically activates executioner caspase 3.
13,65
 
Besides its proteolytic activity in the cytosol, cleaved caspase 3 can also activate caspase 
6, another executioner caspase, and CAD by cleaving its inhibitor (ICAD). CAD 
alongside AIF and endonuclease G, which unlike CAD function in a caspase-independent 
manner, translocate to the nucleus where they lead to DNA fragmentation.
13,51,65 
The extrinsic signaling pathway is activated when death receptors bind their 
natural ligands from the tumor necrosis factor (TNF) family. These death receptors, 
which belong to the TNF receptor family, consist of a cysteine-rich extracellular domain 
for ligand binding and a cytoplasmic domain of 80 amino acids called the death domain 
(DD) involved in signal transduction.
13,48,51
 The best-characterized member of this family 
is Fas receptor, also known as cluster of differentiation 95 (CD95). The Fas receptor is a 
45-kDa trans-membrane protein that binds to its ligand (FasL) through its cysteine-rich 
extracellular domain. Ligand binding induces conformational changes in the receptor 
structure that allows Fas to recruit an adaptor protein called Fas-associated death domain 
(FADD). FADD contains another important motif, the death-effector domain (DED) that 
binds initiator caspases 8 and 10 through complementary DED domains.
13,48,51
 This 
death-inducing signaling complex (DISC) leads to auto-proteolytic cleavage and 
activation of caspases 8 and 10, which subsequently activate executioner caspases 3 and 7 
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to induce apoptotic response (Figure 6).
13,48,51
 The extrinsic pathway may also result in 
the release of cytochrome-c and the induction of the intrinsic pathway through activation 
of BID that serves as a substrate for caspase 8. Upon activation at the DISC, truncated 
BID (tBID) translocates to the mitochondria and induces the release of apoptotic proteins 
from the intermembrane space into the cytosol.
13,28,48
 The extrinsic apoptotic pathway is 
regulated at early stage by FLICE-inhibitory proteins (FLIP), which bind to the DISC and 
inhibit activation of caspase 8.
48,51 
 
Autophagy 
Autophagy is an evolutionary conserved degradative mechanism that is required 
for maintaining cellular homeostasis by recycling and turnover of cytoplasmic 
components. Autophagy is associated with various physiological and pathological 
processes including development, aging, cancer, neurodegenerative disorders and 
infectious diseases.
2,31,55
 Cancer therapeutics also have the ability to induce autophagy 
predominantly through interruption of EGFR pathway, activation of MAPK signaling 
pathways and induction of ER stress.
2
  
Autophagy occurs in three different modes: macroautophagy, microautophagy 
and chaperone-mediated autophagy. Macroautophagy (hereafter referred to as autophagy) 
is the main lysosomal rout for recycling long-lived macromolecules and also organelles, 
such as mitochondria and peroxisomes, when damaged or in excess. It is characterized by 
formation of double-membrane vesicles named autophagosomes around targeted cellular 
components, which directly fuse with lysosomes for enzymatic degradation.  
28 
 
 
 
Figure 6. Intrinsic and extrinsic apoptotic pathways.
19
  The intrinsic pathway is 
controlled by Bcl-2 family of proteins that induce release of cytochrome c from the 
intermembrane space of mitochondria into the cytosol. Cytochrome c causes Apaf-1 to 
bind and activate initiator caspase 9. Cleaved caspase 9 then activates executioner 
caspase 3. On the other hand, the extrinsic pathway is initiated by binding of TNFs to the 
TNFRs. The TNFRs then recruit adaptor protein that can bind and activate initiator 
caspases 8 and 10. These initiator caspases in turn activate caspases 3 and 7. Caspase 8 
can also activate BID, which can translocate to the mitochondria and induce release of 
cytochrome c. 
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Microautophagy involves direct engulfment of cytoplasmic components into the 
lysosome through invagination of the lysosomal membrane, whereas chaperone-mediated 
autophagy is the selective degradation of cytoplasmic proteins, which contain a specific 
motif that can be recognized by lysosomal receptors.
2,31,55 
 Out of 31 autophagy-related genes (ATG) discovered by yeast genetic studies, 18 
genes are involved in autophagosome formation. Since autophagy is an evolutionary 
conserved process, most of these genes have mammalian homologs with similar 
functionality.
23,31,55 
Mammalian ATG9 is a trans-membrane protein essential for autophagosome 
formation that has localizes to the trans-Golgi Network (TGN). Upon starvation, Bax-
interacting factor-1 (Bif-1) co-localizes with ATG9 and induces fragmentation of Golgi. 
The ATG9-containing fragments are dispersed in the cytosol and are utilized for 
autophagosome formation.
55
 This process requires activation of class III PI3K (PI3KC3) 
complex, which consists of PI3KC3, p150, Beclin-1, ultraviolet radiation resistance-
associated gene (UVRAG) and ATG14L that acts upstream of ATG9 trafficking. PI3KC3 
forms a complex with p150 adaptor that tethers the enzyme to the cytoplasmic 
membrane. PI3KC3 then binds Beclin-1 that serves as a binding partner for UVRAG and 
ATG14L. Bif-1 binds the complex by interacting with UVRAG. Activation of PI3KC3 
complex II is regulated by mTOR signaling and is crucial for ATG9 trafficking and 
initiation of autophagosome formation.
23,31,43,55
 Nutrient deprivation inhibits mTOR 
inhibitory effect on Unc51-like kinase 1 (ULK1). Activated ULK1 is recruited by 
ATG14L to directly phosphorylate Beclin-1 and induce activation of PI3KC3. Activated 
PI3KC3 phosphorylates phosphatidylinositol (PI) to produce phosphatidylinositol 3-
30 
 
phosphate (PI3P) that serves as an anchor for PI3P-binding proteins such as ATG18 to 
bind to form phagophores.
43
 Recent studies have shown that there are two 
differentPI3KC3 complexes: complex I contains PI3KC3, p150, Beclin-1 and ATG14L 
whereas in complex II ATG14L is replaced by UVRAG. Complex I is involved in 
Formation of phagophores while complex II contributes to autophagosome 
maturation.
23,43
 The crescent-shaped phagophores, also known as isolation membranes, 
are extended to form double-membrane autophagosomes in a process that involves two 
ubiquitin-like (UBL) conjugation systems. These UBL systems function in a manner that 
resembles the ubiquitylation process involved in protein degradation, which is composed 
of a ubiquitin-activating enzyme (E1), a ubiquitin-conjugating enzyme (E2) and a 
ubiquitin-protein ligase enzyme (E3).
31,35
 In the first UBL system, ATG12 is activated by 
E1-like enzyme ATG7, forming an ATG12-ATG7 thioester intermediate before being 
transferred to ATG10, an E2-like enzyme. In the last step ATG12 covalently binds 
ATG5, and ATG12-ATG5 conjugate non-covalently interacts with ATG16L to form the 
final complex. This complex dissociates from the membrane when autophagosome 
formation process is complete.
31,35
 The second UBL system involves modification and 
incorporation of microtubule-associated Protein 1 Light Chain 3 (LC3) into the 
autophagosome membrane. The C-terminal region of LC3 is first cleaved by ATG4 to 
form LC3-I. E1-like enzyme, ATG7, activates LC3-I, which is then transferred to ATG3, 
an E2 like enzyme. In the final step, LC3-I is covalently bound to 
phosphatidylethanolamine (PE) to form the lipid-protein conjugate LC3-II (Figure 7). 
LC3-II is tightly associated with autophagosomes, and can be used as an autophagic 
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marker in mammalian cells. Upon formation, autophagosomes are fused with lysosomes 
to complete protein degradation.
31,35
  
In addition to bulk degradation of cytoplasmic macromolecules and excessive 
organelles as a result of nutrient deprivation, autophagy can also take part in degradation 
of misfolded proteins. This process is mediated by the adaptor molecule p62 
(sequestosome 1), which possesses specific domains to bind both the ubiquitin moiety on 
the poly-ubiquitinated misfolded proteins and the LC3 on the autophagosome 
membranes. Lysosomal degradation of autophagosomes results in a decrease in p62 
levels, which makes p62 a suitable marker for tracking autophagy in mammalian cells.
12 
Autophagy can induce two opposing responses in cancer cells: protection leading 
to cell survival and cytotoxicity resulting in cell death. Although toxic effects of 
autophagy had been proposed to be accompanied by apoptosis, a study by Saeki et al 
44 
demonstrated that knock down of the anti-apoptotic protein Bcl-2 induced caspase-
independent autophagic cell death, also referred to as programmed cell death type II, by 
increasing the expression of tumor suppressor Beclin-1. This study suggested that 
autophagy can directly induce cell death without activating apoptotic pathways. The 
important role of autophagy in tumor development is further supported by the fact that 
many regulators of this process such as Beclin-1, PTEN, and PI3K/AKT/mTOR pathway 
are commonly mutated or deregulated in a variety of cancers including GBM. Therefore, 
the regulators of autophagy have emerged as attractive targets for development of new 
cancer therapeutics.
14 
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Figure 7. Autophagosome formation in mammalian cells. Inhibition of mTOR due to 
amino acid starvation redepresses ULK1, which then binds ATG14L to phosphorylate 
Beclin-1. Phosphorylation of Beclin 1 activates PI3KC3 in complex I leading to 
production of PIP3 that in turn induces nucleation. Autophagosome formation requires 
two UBL conjugation systems. UBL system 1 produces ATG5-ATG12-ATG16L1 
conjugates that attach the isolation membranes and facilitate membrane nucleation. UBL 
system 2 modifies LC3 and incorporates the final product, LC3-II, into the 
autophagosome membrane. The final step in this process is fusion of the lysosomes with 
the autophagosomes that leads to complete degradation of autophagosome contents. 
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Endoplasmic Reticulum Stress 
 Proteins targeted for secretory pathway are folded in the lumen of endoplasmic 
reticulum (ER) by chaperones before being transported to Golgi apparatus for final 
modification and secretion. Interruption in this process results in accumulation of 
unfolded proteins in the lumen of ER, referred to as ER stress, and induction of the 
unfolded protein response (UPR). The UPR is a series of actions that collectively reduce 
the rate of protein synthesis and activate transcription factors that enhance function of the 
ER.
49,59
 There are three transmembrane proteins in the membrane of ER that sense the 
accumulation of misfolded proteins and trigger the UPR: PKR-like eukaryotic initiation 
factor 2α kinase (PERK), inositol requiring enzyme 1 (IRE1) and activating transcription 
factor-6 (ATF6). This sensory mechanism is mediated by the chaperone protein glucose-
regulated protein of 78 kDa (GRP78), also known as binding immunoglobulin protein 
(BiP), present in the lumen of the ER. Under normal conditions, GRP78 is bound to the 
luminal domains of PERK, IRE1 and ATF6 inhibiting their function. Upon ER stress 
occurrence, GRP78 is released to bind to the unfolded protein leading to the activation of 
the three stress sensors. Upon activation, ATF6 is proteolytically cleaved and directly 
translocated into the nucleus to induce the expression of the genes required for the UPR. 
However, activation of PERK and IRE1 is associated with dimerization and subsequent 
autophosphorylation of specific residues on their cytoplasmic kinase domains.
49,59
 
Activated IRE1, induces formation of  the transcription activator spliced X-box binding 
protein (XBP-1) through splicing of the XBP-1 messenger RNA whereas PERK 
phosphorylates the α subunit of eukaryotic initiation factor 2 (eIF2α) (Figure 8). 
Normally, GTP-bound eIF2 binds to methionyl-transfer RNA and enhances recognition 
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of start codon and is released from ribosomal machinery when GTP is hydrolyzed. 
Phosphorylation of the α subunit of eIF2 inhibits the exchange of GDP for GTP; thus, 
reducing protein synthesis. Furthermore, activated PERK translationally controls the 
expression of activating transcription factor 4 (ATF4) that induces the expression of 
variable UPR-related genes involved in amino acid metabolism, regulation of oxidative 
stress and apoptosis.
59
  
 To prevent aggregation of misfolded proteins in the lumen of ER during ER stress 
XBP1 and ATF6 increase expression of proteins that facilitate ER-associated degradation 
(ERAD).  ERAD is accomplished by retrotranslocation of misfolded proteins into the 
cytosol followed by ubiquitination and proteasomal degradation. ER stress can also 
induce autophagy as an alternate route for protein degradation.
49
 As previously stated, 
this process is regulated by p62, which has the proper domains to bind the ubiquitin 
moiety of the misfolded proteins as well as the LC3 on the autophagosomes.
12 
 Severe ER stress can also induce apoptosis by increasing the expression of group 
III Bcl-2 family of proteins including Puma, Noxa, BIM and BID which induce the 
insertion of proapoptotic proteins Bax and Bak in the mitochondrial membrane, and 
consequently result in the release of cytochrome c.
49
 It has also been suggested that ER 
stress-induced apoptosis occurs through cleavage of caspase 4, a member of caspase 1 
subfamily that localizes to the ER membrane.
22 
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Figure 8. The mechanism of unfolded protein response.
19
 Upon accumulation of 
unfolded proteins in the lumen of the ER, the chaperone GRP78 (BiP) is released from 
the luminal domains of PERK, ATF6 and IRE1. These activated transmembrane proteins 
then trigger cascades of events that collectively result in expression of UPR-related 
genes. Severe ER stress can also induce apoptosis through cleavage of ER membrane-
bound caspase 4.
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MATERIALS AND METHODS  
 
Materials 
Sorafenib Tosylate and Lapatinib Ditosylate were purchased from Selleck 
Chemicals (Radnor, PA). Dr. C.D. James, (UCSF) generously provided primary human 
GBM cells (GBM5, GBM6, GBM12, GBM14) and their genetic background. Dr. S. 
Spiegel (VCU) kindly supplied the plasmid to express green fluorescent protein-tagged 
(GFP) human LC3 for vesicle formation assay. Dulbecco’s Modified Eagle’s Medium 
(DMEM), trypsin-EDTA, penicillin-streptomycin and Phosphate-buffered saline solution 
(PBS) were all purchased from GIBCOBRL (Invitrogen-GIBCOBRL Life Technologies, 
Grand Island, NY). Fetal bovine serum (FBS) was purchased from HyClone 
Laboratories, Inc (Thermo Scientific Hyclone, South Logan, UT). Trypan blue solution, 
formaldehyde, 6-Diamidino-2-Phenylidole (DAPI), and dimethyl sulfoxide (DMSO) 
were all obtained from Sigma Chemical (St. Louis, MO). Recombinant adenoviruses to 
express constitutively activated c-FLIP-s and Bcl-xL and dominant negative (DN) 
caspase 9 were purchased from Vector Biolabs, (Philadelphia, PA). Anti-GAPDH (37 
kDa, 1:1000, mouse monoclonal), anti-phospho-ERK1/2 (42, 44 kDa, 1:1000, mouse 
monoclonal), anti-phospho-Akt (60 kDa, 1:1000, rabbit polyclonal), anti-phospho-eIF2α 
(38 kDa, 1:1000, rabbit monoclonal), anti-puma (23 kDa, 1:1000, rabbit polyclonal), anti-
Mcl-1 (40 kDa, 1:1000, rabbit polyclonal), anti-cleaved caspase 3 (17, 19 kDa, 1:1000, 
rabbit monoclonal), anti-LC3 (14, 16 kDa, LC3II/LC3I, rabbit monoclonal), anti-P62 
(SQSTM1, 65 kDa, 1:1000, mouse monoclonal), anti-GRP78 (78 kDa, 1:1000, rabbit 
monoclonal), anti Beclin-1 (60 kDa, 1:1000, rabbit polyclonal) and anti-ATG5 (55 kDa, 
1:1000, rabbit polyclonal) antibodies were purchased from both Cell Signaling 
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Technologies (Worcester, MA), Santa Cruz Biotechnology (Santa Cruz, CA). Secondary 
antibodies (IRDye 680LT Goat anti-rabbit IgG and IRDye 800CW Goat anti-mouse IgG), 
and Odyssey infrared imaging system blocking buffer were obtained from LI-COR 
Biosciences (Lincoln, NE).  Validated siRNAs were purchased from QIAGEN (Valencia, 
CA).
 
 
Methods 
 
Cell Culture 
All established glioma cell lines (GBM5, GBM6, GBM12 and GBM14), 
originally derived from patients at the Mayo Clinic (Rochester, MN), were cultured in 
Dulbecco’s Modified Eagle’s Medium supplemented with 5% (vol/vol) FBS and 100 
µg/ml (1% vol/vol) penicillin/streptomycin. Cells were incubated in a humidified 
atmosphere of 5% CO2 at 37 °C. For cell viability assays and immunoblotting, cells were 
plated at a density of 2 × 10
4
 (per well of a 12-well plate) for 24-30 hours prior to any 
treatment. 
 
Drug Treatments 
 Plated cells were treated with Lapatinib and Sorafenib, which were taken from a 
10mM stock solution and diluted in DMSO to reach the desired concentration. The 
maximal concentration of vehicle (DMSO) in media was 0.02% (v/v).  
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Infection with Adenovirus: 
Cells were plated in 12-well plates. 24 hours later the media was removed and 
replaced by 1ml of plain DMEM (lacking FBS and penicillin-streptomycin). 
Recombinant adenoviruses to express constitutively activate c-FLIP-s, Bcl-xL and 
dominant negative caspase 9 or empty vector virus were added at a multiplicity of 
infection (MOI) of 50. The plates were incubated for 6 hours and then the plain media 
was replaced by 5% DMEM (supplemented by FBS and penicillin-steptomycin). 
The cells were then treated with indicated concentration of each drug for 24/48 hours 
before being subjected to trypan blue exclusion assay. 
 
 
Plasmid and siRNA Transfections 
For transfection, 0.5 µg of each plasmid was diluted into 50 µl of DMEM medium 
with no added serum or antibiotic and was incubated in solution for 5 minutes at room 
temperature. Concurrently, 1 µl of Lipofectamine 2000 reagent (Invitrogen) was diluted 
into 50 µl of the same medium and was given the same incubation time. After 5 minutes, 
the two solutions were mixed together and incubated at room temperature for 20 minutes. 
The total mix was added to each well containing 400 µl of the same serum/antibiotic free 
medium. Cells were incubated for 6 hours before equal volume (500 µl) of 10% DMEM 
was added to each well. The same procedure was performed for LC3-GFP plasmid 
transfection. 
 In order to down-regulate the expression of Beclin-1 and ATG5, a 10 nM 
concentration of validated siRNA was diluted in 50 µl 0f serum-free medium. 1 µl of 
Lipofectamine 2000 reagent was diluted into 50 µl of the same medium simultaneously, 
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and both solutions were incubated for 5 minutes. The two solutions were then mixed and 
were incubated for 20 minutes. The final solution was added to each well already 
containing serum-free media. After being incubated for 6 hours, an equal volume of 10% 
DMEM was added to each well. 
 
Trypan Blue Exclusion Assay 
  The media from each well of the 12-well plate was transferred into a 15ml tube. 
Attached cells were harvested by trypsinization with trypsin/EDTA for 5 minutes at 37°C 
and then transferred into the corresponding tube. After centrifugation at 1,200 rpm for 5 
minutes the supernatant was removed and the pellet was re-suspended and mixed with the 
vital stain trypan blue. Insertion of trypan blue stain into the cell cytoplasm was used as 
an indicator of cell death. A total of 500 cells from randomly selected fields per 
experimental point were counted using a hemocytometer and a light microscope. The 
percentage of dead cells was expressed as a percentage of the total number of cells 
counted.  
 
Western Blot Analysis 
 
Cells were plated in 60 x 15mm dishes for 24 hours prior to treatment. They were 
treated with the desired concentration of each drug and were incubated for 3, 6, 12 or 24 
hours. After incubation, cells were lysed and scraped using whole-cell lysis buffer (0.5 M 
Tris-HCl, pH 6.8, 2% (w/v) SDS, 10% (v/v) glycerol, 1% (v/v) β-mercaptoethanol, 
0.02% (w/v) bromophenol blue). Collected samples were boiled for 10 minutes and then 
loaded onto 8-14% sodium dodecyl sulfate–polyacrylamide gel (SDS-PAGE). Proteins 
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were electrophoretically separated and transferred onto 0.45 µm PVDF membrane. The 
membrane was blocked in Odyssey blocking buffer. The membrane was then exposed to 
desired primary antibodies overnight. After removal of the primary antibody, the 
membrane was then incubated with the corresponding goat anti-mouse or rabbit 
secondary antibody for 2 hours at room temperature. After being washed three times with 
TBST, the immunoblots were visualized using an Odyssey Infrared Imager (LI-COR 
Biosciences, Lincoln, NE). 
 
 LC3-GFP Vesicle Formation Assay 
 Cells were plated in 4-well glass slide and were transfected with the LC3-GFP 
plasmid. 24 hours after transfection, cells were treated with the indicated drugs and were 
visualized on a ZeissAxiovert 200 micoscope (Carl Zeiss, Wake Forest, NC) 6, 12 and 24 
hours after the treatment. The number of vesicles in 40 cells representing each group was 
counted, and the average vesicles formed in each group was calculated.  
 
Data Analysis 
 The effects of various treatments were analyzed using one-way analysis of 
variance and a two-tailed Student’s t-test. Results with a P value of <0.05 were 
considered statistically significant. 
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Results  
Sorafenib (also referred to as Sor) and lapatinib (also referred to as Lap) have 
recently been subjected to numerous clinical trials either individually or in combination 
with other anticancer agents. First, a dose response test was performed for both drugs 
within the clinically relevant range (Figure 9). Afterwards, both GBM5 and GBM12 cells 
were treated with DMSO, serving as the vehicle group (also referred to as Veh), and a 
combination of either, 1 µM lapatinib and 3 µM sorafenib (not shown) or 2 µM lapatinib 
and 3 µM or 6 µM sorafenib (Figure 10 and 11). Viability was determined by trypan blue 
exclusion assay after 48 hours of drug exposure.  The combination of 2 µM lapatinib and 
6 µM sorafenib in both GBM5 and GBM12 led to cell death in a greater than additive 
manner (Figure 10B and 11B). Conversely, lapatinib (2 µM) in combination with a lower 
concentration of sorafenib (3 µM) failed to produce a similar effect (Figure 10A and 
11A).  Therefore, the combination of 2 µM lapatinib and 6 µM sorafenib was selected for 
all other experiments performed in this manuscript.  
 This selected therapeutic combination effectively induced cell death in a greater 
than additive manner regardless of differing cell type dependent mutations.  This was 
made evident after treatment of GBM6 cells, which express EGFRvIII and GBM14 cells, 
which express mutant PTEN, yielded in similar results (Figure 12). 
 Considering that all GBM cell lines responded similarly to combinational 
treatment with sorafenib and lapatinib, GBM5 and GBM12 cells were utilized for further 
experimentation.  
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Figure 9. Lapatinib and sorafenib dose response in GBM12 cells. 
GBM12 cells were treated with varying concentrations of lapatinib (A) and sorafenib (B) 
within the clinically relevant range, and cell viability was determined by trypan blue 
exclusion assay 48 hours after drug exposure. 
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Figure 10. Assessment of cell viability in GBM5 cells treated with lapatinib and 
sorafenib. GBM5 cells were treated with 2 µM lapatinib combined with two different 
concentrations of 3 µM (A) or 6 µM (B) sorafenib, and cell viability was determined by 
trypan blue exclusion assay 48 hours after drug exposure. 
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Figure 11. Assessment of cell viability in GBM12 cells treated with lapatinib and 
sorafenib. GBM12 cells were treated with 2 µM lapatinib combined with two different 
concentrations of 3 µM (A) or 6 µM (B) sorafenib and cell viability was determined by 
trypan blue exclusion assay 48 hours after drug exposure.  
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Figure 12. Assessment of cell viability in GBM6 and GBM14 cells treated with 
lapatinib and sorafenib. GBM6 (A) and GBM14 (B) cells were treated with either 
lapatinib (2 µM) or sorafenib (6 µM) alone or the combination and cell viability was 
determined by trypan blue exclusion assay 48 hours after drug exposure. 
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Western blot analysis 
 
 To investigate the mechanisms involved in the activation of apoptosis and 
autophagy and to pinpoint the major growth signaling pathways that are affected by the 
combinatorial effect of sorafenib and lapatinib, GBM12 cell lysates were collected 3, 6, 
12 and 24 hours after treatment. The samples were then probed for the proteins involved 
in endoplasmic reticulum stress, autophagy and apoptosis via western blot analysis. The 
data indicated that combinational treatment with lapatinib and sorafenib led to the 
activation of ER stress, as well as the autophagic and apopototic pathways alongside 
inhibition of MAP kinase and PI3K/AKT pathways. 
 As stated previously, both sorafenib and lapatinib inhibit MAP kinase pathway 
through inhibition of Raf kinase and EGFR tyrosine kinases respectively. This effect was 
made evident by the decreasing level of phospho-ERK1/2 observed in response to this 
therapeutic treatment. Phosphorylation of ERK1/2 was modestly inhibited by lapatinib, 
whereas sorafenib demonstrated a greater inhibitory effect. Conversely, the combination 
of sorafenib and lapatinib dramatically reduced the phosphorylation of ERK1/2, 
emphasizing the therapeutic benefit of using these drugs simultaneously. 
In addition, an increase in phosphorylation of eIF2α in response to sorafenib as 
well as the combination of both drugs is a solid indicator of the induction of the unfolded 
protein response.  Accordingly, the expression of Mcl-1 was down-regulated in the same 
groups that demonstrated an increase in phosphorylation of eIF2α. Furthermore, a rapid 
decrease in GRP78 level in response to sorafenib and the combination of sorafenib and 
lapatinib was observed 12 hours after treatment. 
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It was also noted that treatment with lapatinib or sorafenib led to inhibition of the 
PI3K/AKT pathway. Sorafenib individually, and in combination with lapatinib, resulted 
in more potent inhibition in phosphorylation of AKT compared to lapatinib alone. 
 The induction of autophagy was also investigated by examining the expression of 
LC3 isoforms (LC3A and LC3B), Beclin-1 and p62 (sequestosome 1).  Increasing levels 
of total LC3A/B and Beclin-1, predominantly due to exposure of cells to sorafenib or the 
combination of sorafenib and lapatinib, suggested activation of autophagy indicated by 
the presence of autophagosomes. A decrease in p62 level in cells treated with sorafenib 
or the combination is an indicator of lysosomal degradation.  Interestingly, in lapatinib-
treated cells, accumulation of p62 revealed a surprising stall in protein degradation. 
 Finally, an increase in the level of Puma, primarily caused by lapatinib could be 
assumed as an indicator of apoptosis. 
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Figure 13. Western blot analysis of GBM12 cells at 3, 6, 12 and 24 hours after 
exposure to sorafenib and lapatinib. GBM12 cells were treated with lapatinib (2 µM), 
sorafenib (6 µM) or the combination. Cell lysates were collected at 3, 6, 12 and 24 hours 
after the treatment. The samples were then probed for target proteins. 
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The role of autophagy and formation of LC3-GFP vesicle formation in GBM12 cells 
 
 GBM12 cells plated in four-well chamber slides were transfected with a plasmid 
containing LC3-GFP construct, and the formation of the autophagic vesicles was assessed 
by fluorescent microscopy at 6, 12 and 24 hours after the treatment, respectively (Figure 
14A). The number of vesicles in 40 cells representing each group was counted, and the 
average vesicles formed in each group was calculated (Figure 14B). The data showed a 
significant increase in the formation of autophagic vesicles in GBM12 cells as early as 6 
hours after treatment with sorafenib and the combination. This trend stabilized after 12 
hours, with vesicle formation remaining higher after combinational treatment. The extent 
of autophagy in the lapatinib-treated groups was not significant.
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Figure 14. LC3-GFP vesicle formation assay in GBM12 cells treated with sorafenib 
and lapatinib. GBM12 cells were transfected with LC3-GFP plasmid and treated with 
lapatinib (2 µM), sorafenib (6 µM) and the combination. Cells were then visualized by 
fluorescent microscopy at 6, 12 and 24 hours after exposure (A). The number of vesicles 
in 40 cells representing each group was counted, and the average vesicles formed in each 
group was calculated and plotted (B). 
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Knockdown of ATG5 and Beclin 1 reduces the drug combination-mediated toxicity 
in GBM12 and GBM5 cells  
In order to investigate the role of autophagy in lapatinib and sorafenib-mediated 
cell death, Beclin1 and ATG5 were down-regulated. GBM12 and GBM5 cells were 
transfected with control siRNA (SCR), siBeclin1 or siATG5 then subjected to lapatinib, 
sorafenib and the combination of both agents for 24 hours after which cell viability was 
assessed by trypan blue exclusion assay. The results revealed a reduction in cellular 
toxicity in response to sorafenib and sorafenib with lapatinib. Toxicity of lapatinib was 
not affected by inhibition of autophagy (Figure 15 and 16). These findings agreed with 
the data gained from the LC3-GFP vesicle formation assay, emphasizing the significance 
of autophagy in lapatinib and sorafenib combination-mediated toxicity.  
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Figure 15. Knockdown of ATG5 and Beclin-1 reduces drug combination-mediated 
toxicity in GBM12 cells. GBM12 cells were first transfected with either siATG5 or 
siBeclin-1 and then treated with lapatinib (2 µM) and sorafenib (6 µM) or the 
combination. Cell viability was determined by trypan blue exclusion assay 24 hours after 
exposure. *P<0.05 less than corresponding value in siSCR cells. 
 
 
 
 
 
 
 
 
 
 
 
54 
 
P
e
rc
e
n
t 
C
e
ll
 D
e
a
th
0
20
40
60
80
100
V
e
h
S
o
r
L
a
p
L
a
p
+
S
o
r
V
e
h
S
o
r
L
a
p
L
a
p
+
S
o
r
V
e
h
S
o
r
L
a
p
L
a
p
+
S
o
r
siSCR siBeclin1siATG5  
 
 
Figure 16. Knockdown of ATG5 and Beclin-1 reduces drug combination-mediated 
toxicity in GBM5 cells. GBM5 cells were first transfected with either siATG5 or 
siBeclin-1 and then treated with lapatinib (2 µM) and sorafenib (6 µM) or the 
combination. Cell viability was determined by trypan blue exclusion assay 24 hours after 
exposure. *P<0.05 less than corresponding value in siSCR cells. 
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Up-regulation of FLIP and Bcl-xL and down-regulation of caspase 9 reduce the 
drug combination-mediated toxicity in GBM12 and GBM5 cells  
To elucidate the involvement of apoptosis in drug-mediated cell death, GBM12 
and GBM 5 cells were infected with adenoviruses carrying an empty vector (CMV) or the 
constructs designed to either down-regulate caspase 9 via dominant negative mutation 
(DN9) or up-regulate the expression of FLIP or Bcl-xL. Transfected cells were treated 
with sorafenib and lapatinib or the combination for 24 hours and cell viability was 
determined by trypan blue exclusion assay. In GBM12 cells, knockdown of caspase-9, a 
key component of the intrinsic apoptotic pathway, and overexpression of Bcl-xL, an 
antiapoptotic protein, reduced the toxicity of lapatinib and the combination whereas the 
toxicity of sorafenib remained intact. On the other hand, overexpression of FLIP, an 
inhibitor of caspase 8, decreased cell death caused by both sorafenib and the drug 
combination, whereas the toxicity of lapatinib was not affected (Figure 17 and 18). In 
GBM5 cells down-regulation of caspase 9 and up-regulation of Bcl-xL produced similar 
results. However, overexpression of FLIP reduced the toxicity of sorafenib and lapatinib 
individually and in combination (Figure 19). The role of the intrinsic and extrinsic 
apoptotic pathways in drug-mediated cell death was more clearly observed in GBM12 
cells after 48 hour exposure (Figure 20). 
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Figure 17. Overexpression of FLIP and Bcl-xL reduces the toxicity of the drug 
combination in GBM12 cells. GBM12 cells were first infected with recombinant 
adenoviruses to express constitutively activate FLIP and Bcl-xL and then were treated 
with lapatinib (2 µM), sorafenib (6 µM) and the combination. Cell viability was assessed 
by trypan blue exclusion assay 24 hours after exposure. *P<0.05 less than corresponding 
value in CMV cells. 
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Figure 18. Down-regulation of caspase 9 reduces the toxicity of the drug 
combination in GBM12 cells. GBM12 cells were infected with the recombinant 
adenovirus expressing mutant dominant negative caspase 9. Cells were then treated with 
lapatinib (2 µM), sorafenib (6 µM) and the combination. Cell viability was assessed by 
trypan blue exclusion assay 24 hours after exposure. *P<0.05 less than corresponding 
value in CMV cells. 
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Figure 19. Up-regulation of FLIP and Bcl-xL and down-regulation of caspase 9 
reduce the toxicity of the drug combination in GBM5 cells. GBM5 cells were infected 
with recombinant adenoviruses to express constitutively activate FLIP, Bcl-xL and 
dominant negative caspase 9. Cells were then treated with lapatinib (2 µM), sorafenib (6 
µM) and the combination. Cell viability was assessed by trypan blue exclusion assay 24 
hours after exposure. *P<0.05 less than corresponding value in CMV cells. 
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Figure 20. Up-regulation of FLIP and down-regulation of caspase 9 dramatically 
reduce the toxicity of the drug combination in GBM12 cells during 48 hour-drug 
exposure. GBM12 cells were infected with the recombinant adenoviruses expressing 
mutant dominant negative caspase 9 and constitutively active FLIP. Cells were then 
treated with lapatinib (2 µM) and sorafenib (6 µM) simultaneously. Cell viability was 
assessed by trypan blue exclusion assay 48 hours after exposure. *P<0.05 less than 
corresponding value in CMV cells. 
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Knockdown of Fas and FADD reduces the drug combination-mediated toxicity in 
GBM12 cells 
Previous data suggested the involvement of receptor-mediated apoptosis in cells 
treated with sorafenib and the combination of sorafenib and lapatinib. In order to 
elucidate which members of TNF receptor family are involved in this process, Fas and 
Fas-associated death domain (FADD) were knocked down by corresponding siRNAs and 
cell viability was assessed by trypan blue exclusion assay 24 hours after the treatment. 
The results indicated a reduction in toxicity of the drug combination; further confirming 
activation of extrinsic apoptotic pathways (Figure 21). 
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Figure 21. Knockdown of CD95 (Fas) and FADD reduce the toxicity of the drug 
combination in GBM12 cells. GBM12 cells were first transfected with either siCD95 or 
siFADD and then treated with the combination of lapatinib (2 µM) and sorafenib (6 µM). 
Cell viability was determined by trypan blue exclusion assay 24 hours after exposure. 
*P<0.05 less than corresponding value in siSCR cells. 
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Discussion 
 
Although the EGFR signaling pathway is commonly deregulated in GBMs, most 
clinical trials utilizing EGFR inhibitors have not yielded any beneficial outcome. This, in 
part, is due to acquired resistance by which GBM cells bypass the dreadful effects of the 
targeted therapeutics such as lapatinib.
7 
As previously stated, acquiring resistance may be 
through secondary mutations in ErbB receptors, or through crosstalk and activation of 
parallel signaling pathways, or by up-regulation of prosurvival proteins such as Mcl-1.
8
 
In addition, Akhavan et al 
1
 recently showed that de-repression of PDGFRβ, 
predominantly due to ERK activity, promotes resistance to EGFR inhibitors in 
glioblastoma. Moreover, Fenton et al 
15
 suggested that acquired resistance to EGFR 
inhibitors in glioblastoma is mediated by phosphorylation of PTEN at tyrosine 240 which 
leads to loss of PTEN function, through loss of membrane interaction, and consequent 
activation of PI3K/AKT pathway. Since sorafenib is a potent PDGFRβ inhibitor 30,53, and 
has the ability to down-regulate Mcl-1
40,41
 and phospho-AKT 
64
, we hypothesized that 
sorafenib can enhance lapatinib toxicity and improve the treatment efficacy. 
Sorafenib and lapatinib are FDA- approved targeted therapeutics, and their toxic 
effects have been well tolerated by adult patients who received up to 800 mg/day of 
sorafenib or 1500 mg/day of lapatinib.
6,52
 Assessing the cell viability in GBM5, GBM6, 
GBM12 and GBM14 cells treated with the combination of these agents within the 
clinically relevant dose range, we demonstrated that 2 µM lapatinib in combination with 
6 µM sorafenib kill GBM tumor cells in a greater than additive manner (Figure 10B, 11B 
and 12). We also elucidated the mechanisms involved in this drug-mediated cell death.  
63 
 
Rahmani et al 
40,41
 formerly demonstrated that down-regulation of Mcl-1 by 
sorafenib is independent of caspase activation and MEK1/2/ERK1/2 pathway, and 
suggested that sorafenib exerts this effect in a PERK dependent manner. They proposed 
activation of PERK followed by subsequent phosphorylation of eIF2α inhibited protein 
translation leading to a rapid decline of Mcl-1 due to its short half-life.
40,41
 As 
demonstrated in figure 13, an increase in phosphorylation of eIF2α accompanied by a 
rapid decrease in Mcl-1 level in GBM12 cells starting 6 hours after the treatment with 
sorafenib and the combination of sorafenib and lapatinib further approves inhibition of 
translation of Mcl-1 through activation of PERK. Even though activation of PERK is a 
solid indicator of ER stress, interestingly, the level of GRP78, a chaperone with 
cytoprotective function, declined rapidly in response to sorafenib 12 hours after the 
treatment (Figure 13). According to Rahmani et al 
41
, a reduction in GRP78 production, 
predominantly due to inhibition of Raf/MEK1/2/ERK1/2 pathway (decrease in phospho-
ERK1/2 shown in figure 13), contributes to sorafenib-mediated lethality but it is not 
critical since activation of MEK1 did not disrupt sorafenib-mediated cell death. 
Therefore, in this study we further investigated plausible apoptotic pathways that are 
activated in response to sorafenib and lapatinib through overexpressing FLIP or Bcl-xL 
or down-regulating caspase 9. Knockdown of caspase 9 or overexpression of Bcl-xL in 
GBM12 and GBM 5 cells reduced the toxicity of lapatinib (Figure 18 and 19) suggesting 
that lapatinib induces cell death through activation of intrinsic apoptotic pathway, which 
leads to permeabilization of mitochondrial membrane and consequently the release of 
cytochrome c and other apoptotic factors. Elevated level of Puma, a Bcl-2 family member 
that promotes insertion of Bax and Bak in the mitochondrial membrane, observed as early 
64 
 
as 3 hours after exposure to lapatinib confirms activation of porapoptotic proteins. 
Conversely, toxicity of sorafenib was not affected by down-regulation of caspase 9. On 
the other hand, overexpression of FLIP in the same cells suppressed toxicity of sorafenib 
indicating that sorafenib exerts its toxic effect mainly through activation of 
transmembrane death receptors (Figure 17 and 19). Among the members of TNFR 
family, Fas (CD95) and its associated death domain, FADD, were shown to be involved 
in this process since the knockdown of both Fas and FADD reduced combination-
mediated cell death in GBM12 cells (Figure 21). Overexpression of FLIP did not affect 
lapatinib-mediated cell death in GBM12 cells whereas in GBM5 cells a reduction in 
lapatinib toxicity was observed indicating that lapatinib-mediated cell death in GBM5 
cells might involve activation of both intrinsic and extrinsic pathways through crosstalk 
between these two cascades. Overall, our data suggested the combination of sorafenib 
and lapatinib induced cell death in GBM12 and GBM5 cells through activation of both 
intrinsic and extrinsic apoptotic pathways, and inhibition of each pathway individually 
resulted in a dramatic reduction in combination-mediated cell death 48 hours after drug 
exposure (Figure 20).   
 In addition to apoptosis, induction of autophagy was also investigated through 
LC3-GFP vesicle formation assay, western blot analysis and knock down of ATG5 and 
Beclin 1. LC3-GFP vesicle formation assay in GBM12 cells demonstrated a significant 
increase in the formation of autophagic vesicles as early as 6 hours after treatment with 
sorafenib and the combination of sorafenib and lapatinib (figure 14). Western blot 
analysis also showed an increase in total LC3 (isoforms A and B) and Beclin 1 in 
response to the drugs, both individually and in combination (Figure 13). However, 
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evidently sorafenib and the combination of both drugs applied a much stronger effect in 
overexpression of Beclin 1 and formation of autophagosomes. In order to determine the 
role of autophagy in drug-mediated cell death, ATG5 and Beclin 1 were knocked down 
individually in both GBM12 and GBM5 cells. The data showed that inhibition of 
autophagy reduced cell death in cells treated with sorafenib and the combination whereas 
lapatinib-mediated toxicity remained intact. Whether this effect is due to induction of 
cytotoxic autophagy or it occurs in a caspase-dependent manner requires more 
investigation. Surprisingly, accumulation of p62 was observed within the first 6 hours of 
lapatinib exposure in GBM12 cells (Figure 13) showing a stall in lysosomal degradation 
of ubiquitin-tagged proteins. This phenomenon was not observed in cells exposed to 
sorafenib and the combination of both agents, and autophagosome formation was 
followed by lysosomal degradation. 
 
Conclusion 
 In conclusion, in this study we demonstrated that sorafenib in combination with 
lapatinib kill GBM tumor cells in a greater than additive manner in a process that 
involves induction of ER stress, autophagy, intrinsic and extrinsic apoptotic pathways. 
Sorafenib induces cell death mainly through activation of Fas and recruitment of FADD 
whereas lapatinib triggers mitochondria-mediated cell death. We also showed that 
inhibition of autophagy reduced combination-mediated cell death suggesting either the 
occurrence of cytotoxic autophagy or activation of caspase-dependent pathways. 
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